Svenskt forskarlag återställer blodsockerkontrollen hos möss med diabetes

Forskare i Sverige har skapat insulinproducerande celler från mänskliga stamceller som motverkade diabetessymptom vid transplantation i möss. Cellerna mognade efter att ha placerats i ögat och bibehöll glukosreglering under flera månaders tid. Studien har publicerats i Stem Cell Reports.

Forskare vid Karolinska Institutet har utvecklat ett förbättrat protokoll för att utvinna pankreatiska öar från flera mänskliga pluripotenta stamcellslinjer. Metoden använder förfinade odlingsförhållanden och tredimensionella kluster för att reducera oönskade celltyper och förbättra glukosresponsen.

Relaterade artiklar

Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
Bild genererad av AI

Health ministry panel conditionally approves iPS cell products

Rapporterad av AI Bild genererad av AI

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

A team led by Leonardo Ferreira at the Medical University of South Carolina is developing a novel therapy combining lab-made insulin-producing cells with engineered immune cells to protect them. Funded by $1 million from Breakthrough T1D, the approach aims to restore beta cell function without immunosuppressive drugs. This strategy builds on prior research and targets all stages of the disease.

Rapporterad av AI

Researchers have identified why living at high altitudes reduces diabetes risk: red blood cells absorb excess glucose in low-oxygen conditions. This metabolic shift lowers blood sugar levels, as shown in mouse experiments. A new drug mimicking this effect reversed diabetes in mice, suggesting potential treatments.

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Rapporterad av AI Faktagranskad

Researchers at the University of California, Riverside say they have developed a flexible, battery-powered gel patch that generates oxygen inside hard-to-heal wounds—an approach aimed at countering deep-tissue oxygen deprivation that can stall recovery and contribute to amputations. In experiments in diabetic and older mice, the team reported that wounds that often remained open—and were sometimes fatal—closed in about 23 days when treated with the oxygen-generating patch.

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj